| Risperdal Consta (risperidone depot formulation) / J&J |
NCT00253136: A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 458 | US | risperidone | Janssen, LP | Schizophrenia, Psychotic Disorders | | 12/00 | | |
NCT00249223: A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia |
|
|
| Completed | 3 | 641 | Europe | Risperidone Long acting injectable | Janssen Pharmaceutica N.V., Belgium | Schizophrenia, Psychotic Disorders | | 12/00 | | |
NCT00034775: A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. |
|
|
| Completed | 3 | 141 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 10/02 | | |
NCT00236457: A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 629 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Psychotic Disorders | | 12/02 | | |
NCT00236548: Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection |
|
|
| Completed | 3 | 1 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Psychotic Disorders | | 01/03 | | |
NCT00236353: Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 86 | US | risperidone | Janssen, LP | Schizophrenia, Psychotic Disorders | | 12/03 | | |
NCT00210691: A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 273 | US | Risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/04 | | |
NCT00236587: A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia |
|
|
| Completed | 3 | 100 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 02/04 | | |
NCT00297388: A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 40 | US | Risperidone, long-acting injectable | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 09/04 | | |
NCT00558298: A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder. |
|
|
| Completed | 3 | 811 | US | risperidone | Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 02/05 | | |
NCT00495118: A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients. |
|
|
| Completed | 3 | 314 | US | risperidone | Janssen, LP | Schizophrenia, Schizoaffective Disorder | | 03/05 | | |
NCT00828958: Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients. |
|
|
| Completed | 3 | 53 | US | Risperidone long-acting injectable | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 09/06 | | |
NCT00210717: A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia |
|
|
| Completed | 3 | 748 | US | paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 04/07 | | |
NCT00216476: A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 3 | 753 | Europe, RoW | Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine | Janssen-Cilag International NV | Schizophrenia, Psychotic Disorders | 11/07 | 11/07 | | |
NCT00589914: Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia |
|
|
| Completed | 3 | 1221 | US, Europe, RoW | RISPERDAL CONSTA, Paliperidone palmitate | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 06/09 | 06/09 | | |
